Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation: Acute Stroke With Xarelto to Reduce Intracranial Bleeding, Recurrent Embolic Stroke, and Hospital Stay, Phase 2, Conceptual Multicenter Trial

Trial Profile

Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation: Acute Stroke With Xarelto to Reduce Intracranial Bleeding, Recurrent Embolic Stroke, and Hospital Stay, Phase 2, Conceptual Multicenter Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Warfarin
  • Indications Intracranial embolism; Intracranial haemorrhages; Stroke
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TripleAXEL
  • Most Recent Events

    • 11 Sep 2017 Results published in the JAMA Neurology
    • 20 Jul 2016 Status changed from recruiting to completed.
    • 08 May 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top